品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com
商品描述
Description:C5,Mouse,mAbBB5.1
ThemonoclonalantibodyBB5.1bindsthefifthcomponentofmousecomplement(C5).Thecomplementsystemisagroupofplasmaandcellmembraneproteinsthatplayakeyroleintheimmunesystem.Allthreepathways(classical,alternative&lectin)leadtothecleavageofC3andeventuallytheformationofthecytolyticmembraneattackcomplexC5b-9.IftheactivationcascadeisallowedtoproceedbeyondthecleavingofC3intoC3aandC3b,anadditionalC3bmoleculebindstotheC3convertases.ThisgeneratestheC5convertase(C3bBbC3bforthealternativepathwayandC4bC2bC3bfortheclassicalandlectinpathways).C5convertasecleavesC5,releasesthepotentanaphylacticpeptideC5aandgeneratesC5b.C5bcaninitiatetheterminalpathway,whichrecruitsthecomponentsC6,C7,C8andC9tothesurfaceofthetargetandinsertstheC9complexasapore(termedtheterminalcomplementcomplex)intothemembrane.C5aisthemostpotentanaphylatoxinandapowerfulchemotaxinforneutrophilsandmonocytes,withtheABIlitytopromotemargination,extravasation,andactivationofthesecells.Thus,blockingC5mayberequiredforoptimalinhibitionoftheinflammatoryresponse.Atthesametime,inhibitionofthecomplementcascadeatC5doesnotimpairthegenerationofC3bthroughtheclassicalandalternativepathways,preservingC3b-mediatedopsonizationofpathogenicmicroorganismsaswellasopsonizationandsolubilizationofimmunecomplexes.
C5issynthesisedintheliverasasinglepolypeptidechainandispresentinseruminaconcentrationof50-80 µm/ml.Beforesecretionthemoleculeisglycosylatedandsecretedintoplasmaasa190kDaglycoproteinconsistingofadisulphidelinkedalpha-chain(111kDa)andbeta-chain(75kDa).MonoclonalantibodyBB5.1hasbeenshowntoprecipitatethetwochainsofC5fromnormalmouseserumandinhibitedC5-dependenthemolysisinafunctionalcomplementtest.FurThermore,BB5.1admiNISTrationcompletelyinhibitsterminalcomplementactivityinmurinemodelsforantibody-mediatedrejection(AMR)duringheartandkidneytransplantation.Inanothermousemodel,bothpre-treatmentaswellasinterventionwithmonoclonalantibodyBB5.1attenuatesdiseasedevelopmentduringanti-MPOIgG-inducedglomerulonephritis.BlockageofC5activationbyBB5.1protectsagainstrenalischemia-reperfusioninjurybyinhibitionoflateapoptosisandinflammation.InLupusdisease,combinationtherapyofanti-IL-10/anti-C5(BB5.1)canbothpreventandreducetheeffectofthehumoralimmuneresponse
C5issynthesisedintheliverasasinglepolypeptidechainandispresentinseruminaconcentrationof50-80 µm/ml.Beforesecretionthemoleculeisglycosylatedandsecretedintoplasmaasa190kDaglycoproteinconsistingofadisulphidelinkedalpha-chain(111kDa)andbeta-chain(75kDa).MonoclonalantibodyBB5.1hasbeenshowntoprecipitatethetwochainsofC5fromnormalmouseserumandinhibitedC5-dependenthemolysisinafunctionalcomplementtest.FurThermore,BB5.1admiNISTrationcompletelyinhibitsterminalcomplementactivityinmurinemodelsforantibody-mediatedrejection(AMR)duringheartandkidneytransplantation.Inanothermousemodel,bothpre-treatmentaswellasinterventionwithmonoclonalantibodyBB5.1attenuatesdiseasedevelopmentduringanti-MPOIgG-inducedglomerulonephritis.BlockageofC5activationbyBB5.1protectsagainstrenalischemia-reperfusioninjurybyinhibitionoflateapoptosisandinflammation.InLupusdisease,combinationtherapyofanti-IL-10/anti-C5(BB5.1)canbothpreventandreducetheeffectofthehumoralimmuneresponse
Specifications:
| Catalognumber | HM1073-5B |
|---|---|
| Producttype | Monoclonalantibodies |
| Quantity | 5mg |
| Formulation | 5mg0.2μmfilteredproteinGpurifiedantibodysolutioninPBSwithaconcentrationofatleast0.5mg/ml(exactconcentrationisindicatedonthelabel).Theendotoxinconcentrationis<24EU/mg,determinedwithHIT302LALAssay. |
| Application | Frozensections,Functionalstudies,Immunoassays,Immunofluorescence,Immunoprecipitation,Paraffinsections |
| ApplicationNotes | FS:exvivo:50 µgmAb/mlserum;invivo:BALB/cmice40mgmAb/kg/day,0-2daysfollowedbytwiceaweek. IA:Wellswerecoatedwith2-4 µgpurifiedBB5.1inPBSascoatantibodyforuseinELISA. IP:Mouseserumwaspre-adsorbedwithαmouse-Igaffinitygelandprot-A-sepharosefor30minatRT.ThenC5wasprecipitatedwithBB5.1(10 µgmAb/mlfollowedbyprot-Asepharosefor1h).Precipitatedsampleswereanalysedon7%SDS/PAGE. |
| Use | Dilutionstobeuseddependondetectionsystemapplied.Itisrecommendedthatuserstestthereagentanddeterminetheirownoptimaldilutions.Thetypicalstartingworkingdilutionis1:50. |
| Immunogen | PurifiedC5 |
| Isotype | MouseIgG1 |
| Species | Mouse |
| Crossreactivity | Rat-Yes |
| Alias | ComplementC5,Hemolyticcomplement Genename:C5 |
| References | 1.Frei,Yetal;GenerationofamonoclonalantibodytomouseC5applicationinanELISAassayfordetectionofanti-C5antibodies.MolCellProbes1987,1:141 2.Thurman,Jetal;C3aisrequiredfortheproductionofCXCchemokinesbytubularepithelialcellsafterrenalischemia/reperfusion.JImmunol2007,178:18193.Mihai,Setal;Thealternativepathwayofcomplementactivationiscriticalforblisterinductioninexperimentalepidermolysisbullosaacquisita.JImmunol2007,178:6514 4.Wang,Hetal;Inhibitionofterminalcomplementcomponentsinpresensitizedtransplantrecipientspreventsantibody-mediatedrejectionleADIngtolong-termgraftsurvivalandaccommodation.JImmunol2007,179:44515.Huugen,Detal;InhibitionofcomplementfactorC5protectsagainstantimyeloperoxidaseantibody-mediatedglomerulonephritisinmice.KidneyInt2007,71:646 6.Nilsson,Ketal.Enhancedsusceptibilitytolow-dosecollagen-inducedarthritisinCR1/2-deficientfemalemice–possIBLeroleofestrogenonCR1expression.Faseb2009,23:24507.Copland,Detal.Systemicandlocalanti-C5therapyreducesthediseaseseverityinexperimentalautoimmuneuveoretinitis.Clinexpimmunol2010,159:303 8.Pavlovski,Detal;GenerationofcomplementcomponentC5abyischemicneuronspromotesneuronalapoptosis,Faseb2012,26:3680 |
| Storageandstability | Productshouldbestoredat4 °C.Underrecommendedstorageconditions,productisstableforatleastoneyear. |
| Precautions | Forresearchuseonly.Notforuseinoronhumansoranimalsorfordiagnostics.Itistheresponsibilityoftheusertocomplywithalllocal/stateandfederalrulesintheuseofthisproduct.HycultBiotechisnotresponsibleforanypatentinfringementsthatmightresultwiththeuseorderivationofthisproduct. |
| Disease | Infectiousdiseases,Nephrology |
